The overall goals of this grant are to: a) understand the role of epigenetic gene silencing in cancer through studying the function of novel genes which have aberrant promoter hypermethylation; and b) dissect molecular mechanisms by which this promoter change participates in transcriptional silencing and through which it arises during cancer evolution. In the first specific aim, we have created a mouse knockout model for HIC-1 (Hypermethylated-in-Cancer-1), a gene cloned by screening for hypermethylated loci in a frequent LOH area for human cancers, 17p13.3. Hic-1 mice manifest an age dependent, gender specific, tumor spectrum and the wild type allele is lost in the tumors solely through promoter methylation. The loss of Hic-1 also profoundly alters tumor spectrum and aggressiveness in p53 mice including appearance of breast cancers. We will create new models for breast and other cancers based on this loss of Hic-1 function as a requisite early step. In the second specific aim, we have identified the developmental gene, ephrin A1, as a direct transcriptional repression target of HIC-1. We will study the significance of this for HIC-1 anti-tumor effects by: a) exploring whether ephrin AlsiRNA knockdown in human breast cancer cells reproduces effects of exogenous over-expression of HIC-1; and b) targeting overexpression of ephrin A1 to breast epithelium in a transgenic mouse. In the third specific aim, we identify that different histone modifications (the """"""""histone code"""""""") mark promoter regions of transcriptionally silent and hypermethylated genes versus these same genes when they are unmethylated and expressed. Drug induced (5-deoxy-azacytidine-DAC) reversal of the hypermethylation leads to gene re-expression and loss of the transcriptional silencing histone marks and gain of transcriptional activation marks. We are exploring the hypothesis that the demethylation triggers these events through directly activating transcription which then prompts a nucleosome switch involving variant histones to account for loss of the silencing histone marks and gain of the transcriptional activation histone modifications.
In specific aim # 4, we explore whether methylation of lysine 9 of histone H3 serves as a signal for triggering DNA methylation associated with cancer gene silencing. Our data in studies of a hypermethylated p16 gene in colon cancer ceils indicates that this may be the case. We will determine, through ChIP localization assays, and gene knockdown and over-expression studies, which specific methyl K9:H3 methyltransferases may trigger this histone modification and thus may establish aberrant promoter DNA hypermethylation in cancer cells. A final specific aim links all of those above by exploring the hypothesis that specific chromatin changes may explain the gender differences in the spectrum of tumors seen in mice with disruption of the gene being studied in Specific Aims #'s 1 and 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043318-21
Application #
7068500
Study Section
Special Emphasis Panel (ZRG1-CG (01))
Program Officer
Okano, Paul
Project Start
1986-09-30
Project End
2009-04-30
Budget Start
2006-06-01
Budget End
2007-04-30
Support Year
21
Fiscal Year
2006
Total Cost
$439,060
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Vaz, Michelle; Hwang, Stephen Y; Kagiampakis, Ioannis et al. (2017) Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell 32:360-376.e6
Zhang, Yang W; Wang, Zhihong; Xie, Wenbing et al. (2017) Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. Mol Cell 65:323-335
Chiappinelli, Katherine B; Zahnow, Cynthia A; Ahuja, Nita et al. (2016) Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res 76:1683-9
Sen, Subhojit; Block, Kirsten F; Pasini, Alice et al. (2016) Genome-wide positioning of bivalent mononucleosomes. BMC Med Genomics 9:60
Easwaran, Hariharan; Tsai, Hsing-Chen; Baylin, Stephen B (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54:716-27
Ahuja, Nita; Easwaran, Hariharan; Baylin, Stephen B (2014) Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124:56-63
Cai, Y; Geutjes, E-J; de Lint, K et al. (2014) The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 33:2157-68
Cui, Ying; Hausheer, Frederick; Beaty, Robert et al. (2014) A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Res 74:3834-43
Park, Tea Soon; Bhutto, Imran; Zimmerlin, Ludovic et al. (2014) Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. Circulation 129:359-72
Azad, Nilofer; Zahnow, Cynthia A; Rudin, Charles M et al. (2013) The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol 10:256-66

Showing the most recent 10 out of 108 publications